Search research articles
Contact Us
Filters
Showing results (11-20 of 108) with videos related to
Page
of 11
Sort By:
Bioorganic & Medicinal Chemistry Letters
|
February 27, 2017
Continued optimization of the M<sub>5</sub> NAM ML375: Discovery of VU6008667, an M<sub>5</sub> NAM with high CNS penetration and a desired short half-life in rat for addiction studies
Kevin M McGowan, Kellie D Nance, Hykeyung P Cho, et al.
Drug News & Perspectives
|
June 4, 2010
The antipsychotic potential of muscarinic allosteric modulation
Thomas M Bridges, Evan P LeBois, Corey R Hopkins, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 13, 2015
A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo
Anna L Blobaum, Frank W Byers, Thomas M Bridges, et al.
Chemical Reviews
|
February 17, 2016
Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors
Craig W Lindsley, Kyle A Emmitte, Corey R Hopkins, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 11, 2012
Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere
Jason D Downey, Sam A Saleh, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 17, 2009
Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM
Thomas M Bridges, J Phillip Kennedy, Hyekyung P Cho, et al.
ACS Chemical Neuroscience
|
February 24, 2017
Disease-Modifying Effects of M<sub>1</sub> Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model
Evan P Lebois, Jason P Schroeder, Thomas J Esparza, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 22, 2017
Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype
Aaron M Bender, Rebecca L Weiner, Vincent B Luscombe, et al.
ACS Pharmacology & Translational Science
|
April 8, 2020
<i>In Vitro</i> to <i>in Vivo</i> Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery
Karen J Gregory, Thomas M Bridges, Rocco G Gogliotti, et al.
ACS Chemical Neuroscience
|
July 12, 2017
Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators
Joshua M Wieting, Anish K Vadukoot, Swagat Sharma, et al.
Page
of 11
Search research articles
Search
Showing results (11-20 of 108) with videos related to
Sort By:
Page
of 11
Bioorganic & Medicinal Chemistry Letters
|
February 27, 2017
Continued optimization of the M<sub>5</sub> NAM ML375: Discovery of VU6008667, an M<sub>5</sub> NAM with high CNS penetration and a desired short half-life in rat for addiction studies
Kevin M McGowan, Kellie D Nance, Hykeyung P Cho, et al.
Drug News & Perspectives
|
June 4, 2010
The antipsychotic potential of muscarinic allosteric modulation
Thomas M Bridges, Evan P LeBois, Corey R Hopkins, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 13, 2015
A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo
Anna L Blobaum, Frank W Byers, Thomas M Bridges, et al.
Chemical Reviews
|
February 17, 2016
Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors
Craig W Lindsley, Kyle A Emmitte, Corey R Hopkins, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 11, 2012
Development of an in vivo active, dual EP1 and EP3 selective antagonist based on a novel acyl sulfonamide bioisostere
Jason D Downey, Sam A Saleh, Thomas M Bridges, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 17, 2009
Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM
Thomas M Bridges, J Phillip Kennedy, Hyekyung P Cho, et al.
ACS Chemical Neuroscience
|
February 24, 2017
Disease-Modifying Effects of M<sub>1</sub> Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model
Evan P Lebois, Jason P Schroeder, Thomas J Esparza, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 22, 2017
Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype
Aaron M Bender, Rebecca L Weiner, Vincent B Luscombe, et al.
ACS Pharmacology & Translational Science
|
April 8, 2020
<i>In Vitro</i> to <i>in Vivo</i> Translation of Allosteric Modulator Concentration-Effect Relationships: Implications for Drug Discovery
Karen J Gregory, Thomas M Bridges, Rocco G Gogliotti, et al.
ACS Chemical Neuroscience
|
July 12, 2017
Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators
Joshua M Wieting, Anish K Vadukoot, Swagat Sharma, et al.
Page
of 11